Degarelix Adverse Events: What Studies Report
Degarelix is an approved prescription injectable gonadotropin releasing hormone receptor antagonist used in advanced prostate cancer. Published randomised trials and reviews most often described injection site reactions, hot flushes and other consequences of lowered testosterone, including effects on sexual function, body composition, bone and metabolic measures. A dedicated randomised cardiovascular outcomes trial compared degarelix with leuprolide and ended early. This page groups reported adverse events by system and notes where structured frequency data were not available. The prescribing clinician decides whether and how the medicine is used.
Degarelix is an approved prescription medicine. It is a gonadotropin releasing hormone (GnRH) receptor antagonist given by subcutaneous injection and is authorised by medicines regulators for the treatment of advanced hormone sensitive prostate cancer, where it is used as a form of androgen deprivation therapy. Published reviews of the androgen deprivation landscape describe degarelix within the injectable GnRH antagonist class alongside agonist therapies and the oral antagonist relugolix (PMID 39555581). This page summarises what clinical trials, reviews and labeling have reported about adverse events. It does not give instructions, and whether degarelix is used at all, and in what way, is decided by the prescribing clinician.
For background on what the molecule is, see the degarelix glossary entry, the explainer on how degarelix works, and the overview of what degarelix is used for.
Where the adverse event evidence comes from
Most structured safety information for degarelix comes from randomised controlled trials in men with prostate cancer, from a dedicated randomised cardiovascular outcomes trial, and from narrative and systematic reviews that pooled those trial reports. A pivotal 12 month, comparative, randomised, open label, parallel group phase III study compared degarelix with the GnRH agonist leuprolide in patients with prostate cancer and reported efficacy and safety outcomes side by side (PMID 19035858). A later drug review collected the safety data accumulated in patients with prostate cancer treated with degarelix (PMID 24756432), and further reviews examined whether the adverse event profile of GnRH antagonists differs from that of agonists (PMID 32655041).
Two limitations run through this literature. First, many trials were open label, which can influence how subjective events such as injection site discomfort are recorded, as in the phase III comparison described by researchers (PMID 19035858). Second, several comparative questions, particularly cardiovascular ones, have been addressed mainly by observational analyses and post hoc pooling rather than by adequately powered randomised trials, a gap discussed in a review of the cardiovascular effects of GnRH antagonists in men with prostate cancer (PMID 33470403).
Injection site and local reactions: What Studies Report
The most distinctive adverse events described for degarelix are local. Because the medicine is administered subcutaneously and forms a depot at the injection site, the pivotal randomised phase III comparison with leuprolide reported injection site reactions, including pain, erythema and swelling, substantially more often in the degarelix groups than in the agonist comparator group, with most such events described as mild to moderate and occurring mainly after the initial administration (PMID 19035858). A review of degarelix in patients with prostate cancer identified injection site reactions as the characteristic tolerability issue that separates this agent from intramuscular agonist depots (PMID 24756432). An earlier review of degarelix as a GnRH blocker for prostate cancer described the same local reaction pattern in the development programme (PMID 19450172), and a comparative review of degarelix versus luteinising hormone releasing hormone agonists treated injection site reactions as the main tolerability trade off against the absence of an initial testosterone surge (PMID 28480768).
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeAndrogen deprivation effects: What Studies Report
Because degarelix suppresses testosterone, most systemic adverse events reported in trials are the expected consequences of hypogonadism rather than effects unique to the molecule. Reviews of androgen deprivation therapy describe hot flushes, fatigue, reduced libido, erectile dysfunction, mood changes and gynaecomastia as the recurring symptom cluster across agonist and antagonist treatments (PMID 32655041). The randomised phase III comparison reported hot flushes among the most common adverse events in both the degarelix and leuprolide arms (PMID 19035858), and a review of the androgen deprivation landscape placed these symptoms at the centre of the tolerability discussion for all testosterone lowering strategies (PMID 39555581).
One class difference that reviews emphasise is mechanistic rather than symptomatic. Reviews of GnRH antagonists in advanced prostate cancer described immediate receptor blockade without the initial surge in luteinising hormone and testosterone that follows agonist initiation, and therefore without the clinical flare phenomena linked to that surge (PMID 20398443). A 2025 review of GnRH antagonists in prostate cancer restated this profile while summarising the current evidence base for the class (PMID 40776862).
Cardiovascular events: What Studies Report
Cardiovascular safety has been the most actively studied comparative question. The PRONOUNCE randomised trial compared degarelix with leuprolide in patients with prostate cancer and pre-existing cardiovascular disease, using major adverse cardiovascular events over 12 months as the primary endpoint, and researchers reported that the trial was terminated early because enrolment was slower than planned and that no significant difference between the two treatments was demonstrated in the primary analysis (PMID 34459214). The authors described the trial as underpowered for its original question as a result of early termination (PMID 34459214).
Before that trial reported, a review of the cardiovascular effects of GnRH antagonists in men with prostate cancer examined signals from pooled trial data and observational series and concluded that the available evidence was limited and inconsistent (PMID 33470403). A review asking whether GnRH antagonists are safer with respect to androgen deprivation side effects reached a similarly cautious reading of the comparative cardiovascular literature (PMID 32655041), and a comparative review of degarelix versus luteinising hormone releasing hormone agonists discussed the same unresolved question (PMID 28480768).
Tracking research? Log entries with dates, lots and notes: records, never plans.
Get the appMetabolic, body composition and bone outcomes: What Studies Report
Reviews of androgen deprivation therapy describe loss of bone mineral density, increased fat mass, reduced lean mass, insulin resistance and adverse changes in lipid measures as recognised longer term consequences of sustained testosterone suppression across the drug class (PMID 32655041). A review of the androgen deprivation landscape for advanced prostate cancer discussed these metabolic and skeletal consequences as part of the overall treatment burden rather than as agent specific findings (PMID 39555581). Reviews of degarelix specifically have not established that its metabolic or skeletal profile differs in a clinically defined way from that of agonist therapy, and a 2025 review of the antagonist class described the comparative evidence as still developing (PMID 40776862).
Laboratory and haematological findings: What Studies Report
Trial and review reporting of laboratory changes is less granular than reporting of symptomatic events. The randomised phase III study collected laboratory safety data alongside clinical adverse events over 12 months of treatment (PMID 19035858), and the drug review summarising degarelix in patients with prostate cancer compiled tolerability findings from that programme (PMID 24756432). Isolated haematological events have appeared in the case literature rather than in controlled datasets: a single case report described severe neutropenia in a patient with metastatic hormone sensitive prostate cancer and attributed the event to palliative radiation therapy (PMID 39498195). Single case reports cannot establish frequency or causation for any medicine.
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeSummary table of reported events by system
| Body system | What was reported | Evidence type | Source |
|---|---|---|---|
| Injection site | Pain, erythema and swelling, mostly mild to moderate and more frequent than with the agonist comparator | Randomised open label phase III trial; reviews | PMID 19035858, PMID 24756432 |
| Vasomotor | Hot flushes among the most common events in both treatment arms | Randomised phase III trial; class reviews | PMID 19035858, PMID 32655041 |
| Sexual and general | Reduced libido, erectile dysfunction, fatigue, gynaecomastia described as androgen deprivation effects | Narrative reviews | PMID 32655041, PMID 39555581 |
| Cardiovascular | No significant difference demonstrated versus leuprolide in a trial stopped early for slow enrolment | Randomised cardiovascular outcomes trial; review | PMID 34459214, PMID 33470403 |
| Bone and metabolic | Bone mineral density loss, body composition and metabolic changes described for androgen deprivation generally | Narrative reviews | PMID 32655041, PMID 40776862 |
| Haematological | Severe neutropenia in one patient, attributed by the authors to palliative radiation therapy | Single case report | PMID 39498195 |
Class context: oral antagonist data
Adverse event discussions for degarelix are often read alongside data for the oral GnRH antagonist relugolix. A 2024 report in JAMA Oncology examined the efficacy and safety of radiotherapy plus relugolix in men with localized or advanced prostate cancer and reported adverse events in that combined treatment setting (PMID 38451492). Findings from an oral agent do not transfer directly to an injectable depot, particularly for local reactions, a distinction underlined by reviews of the antagonist class (PMID 40776862).
Where structured adverse event data are limited
- Long term comparative data beyond the 12 month horizon of the pivotal randomised phase III study are sparse (PMID 19035858).
- The dedicated randomised cardiovascular trial ended early, so precise event rate comparisons were not established (PMID 34459214).
- Comparative cardiovascular evidence outside that trial came largely from pooled and observational analyses, as noted in a dedicated review (PMID 33470403).
- Agent specific frequency data for bone and metabolic outcomes are limited, with reviews describing class level effects of androgen deprivation instead (PMID 32655041).
- Rare haematological events appear in case reports, which cannot define incidence (PMID 39498195).
Who decides about this medicine
Degarelix is a regulator approved prescription medicine used under medical supervision in oncology care. The prescribing clinician decides whether it is appropriate, how it is administered and how adverse events are monitored and managed. Any personal question about symptoms, monitoring, interactions or alternatives belongs with that clinician and cannot be answered by a summary of published literature. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition or treatment.
References
- The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer (BJU International, 2008)
- Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer (Future Oncology, 2009)
- GnRH antagonists in the treatment of advanced prostate cancer (The Canadian Journal of Urology, 2010)
- Degarelix: a review of its use in patients with prostate cancer (Drugs, 2014)
- Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer (Expert Opinion on Pharmacotherapy, 2017)
- Androgen deprivation therapy and side effects: are GnRH antagonists safer? (Asian Journal of Andrology, 2021)
- Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial (Circulation, 2021)
- The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer (European Heart Journal Cardiovascular Pharmacotherapy, 2022)
- Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer (JAMA Oncology, 2024)
- The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer (Future Oncology, 2024)
- Severe neutropenia caused by palliative radiation therapy in a case of metastatic hormone-sensitive prostate cancer (IJU Case Reports, 2024)
- GnRH Antagonists: Current Evidence and Role in Prostate Cancer (Archivos Espanoles de Urologia, 2025)
Frequently asked questions
What adverse events were most commonly reported in degarelix trials?▾
The pivotal 12 month randomised open label phase III study in patients with prostate cancer reported injection site reactions such as pain, erythema and swelling far more often in the degarelix groups than in the agonist comparator group, together with hot flushes in both arms (PMID 19035858). A later review of degarelix in prostate cancer identified local injection site reactions as the characteristic tolerability finding (PMID 24756432).
What did the randomised cardiovascular trial of degarelix report?▾
The PRONOUNCE trial compared degarelix with leuprolide in patients with prostate cancer and pre-existing cardiovascular disease, using major adverse cardiovascular events at 12 months as the primary endpoint. Researchers reported that the trial was terminated early because of slower than expected enrolment and that no significant difference was demonstrated between the treatments in the primary analysis (PMID 34459214).
Are the side effects of GnRH antagonists different from those of agonists?▾
A review asking whether GnRH antagonists are safer concluded that both approaches produce the symptom cluster associated with testosterone suppression, and that comparative evidence for differences in longer term harms remained limited (PMID 32655041). Reviews of the antagonist class also described immediate receptor blockade without the initial testosterone surge seen after agonist initiation (PMID 20398443).
What effects on bone and metabolism have been described?▾
Reviews of androgen deprivation therapy described loss of bone mineral density, increased fat mass, reduced lean mass, insulin resistance and lipid changes as recognised consequences of sustained testosterone suppression across the drug class rather than as findings unique to one agent (PMID 32655041). A review of the androgen deprivation landscape discussed these outcomes as part of overall treatment burden (PMID 39555581).
Has neutropenia been linked to degarelix in published reports?▾
A single case report described severe neutropenia in a patient with metastatic hormone sensitive prostate cancer and attributed the event to palliative radiation therapy rather than to hormonal treatment (PMID 39498195). Single case reports cannot establish incidence or causation. Controlled safety reporting for degarelix came mainly from the randomised phase III programme (PMID 19035858).
Where is the adverse event evidence for degarelix weakest?▾
Comparative cardiovascular evidence outside one randomised trial came largely from pooled and observational analyses, which a dedicated review described as limited and inconsistent (PMID 33470403). The randomised cardiovascular trial itself ended early (PMID 34459214), and agent specific frequency data for bone and metabolic outcomes remain sparse, with reviews reporting class level effects instead (PMID 32655041).
Who decides whether degarelix is used?▾
Degarelix is an approved prescription medicine administered under medical supervision in oncology care, and the prescribing clinician decides whether it is appropriate and how administration and monitoring are handled. Published sources describe trial populations and reported events, such as the comparative phase III dataset (PMID 19035858) and class reviews (PMID 40776862), not individual treatment decisions.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education. It is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.